Antigen Presentation and Lymphocyte Response in Parkinson's Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 95
- 试验地点
- 3
- 主要终点
- Percentage of subjects with T-cell immune response
研究概览
简要总结
The way the immune system responds to certain PD-related proteins in PD donors compared to the way it responds in persons without or fewer PD related proteins is not well studied and this study aims to analyze the autoimmune response in each group. The study involves a one time visit involving brief questionnaires and a blood draw of 30 mL (approximately 2 tablespoons) to be collected.
详细描述
The role of the immune response in Parkinson's disease (PD) is controversial. Recent studies show that neurons can present MHC-I (major histocompatibility complex - class 1) molecules and therefore may be susceptible to an attack by immune cells. The investigators anticipate that the results of this study will improve our understanding of the mechanisms of immune mediated neuronal degeneration in PD. Initial results suggest that antigens are presented by neuronal MHC-I in PD, and that this could lead to T-cell mediated neuronal death. The most obvious antigen that could be differentially expressed in PD patients and controls would be alpha-synuclein (-syn): -syn oligomers appear in all Lewy bodies and Lewy neurites and are the hallmark of PD changes in the brain. This study will offer the opportunity to further characterize the immune mediated component of PD, and to continue elucidating the biology that underlies antigen presentation and T-cell cytolytic activity.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Moderate to advanced PD with classic motor features, and must demonstrate two of the following three: rest tremor, rigidity, or bradykinesia
- •Dopaminergic medication benefit (self-reported improvement)
- •Age at recruitment: 50 - 90 years
- •Age at diagnosis > 47
- •PD duration > 3 years
- •Willingness to have genotyping and genetic studies as part of laboratory research
排除标准
- •Atypical parkinsonism or other neurological disorders
- •Recent history of cancer (past 3 years)
- •Autoimmune disease (except thyroid disease)
- •On chronic immune-modulatory therapy (e.g. SIT (specific immunotherapy), anti-IgE)
- •Inability to provide informed consent
结局指标
主要结局
Percentage of subjects with T-cell immune response
时间窗: Day 1-2
Blood samples from PD patients and controls will be processed. The presence of T cell response against the candidate antigens by patient blood-derived peripheral blood mononuclear cells (PBMC) will be assessed using an enzyme-linked immunosorbent spot (ELISPOT) assay.
次要结局
未报告次要终点
研究者
Roy Alcalay
Principal Investigator
Columbia University